Sandoz enters into biosimilar partnership with Biocon
22-01-2018
solidcolours / iStockphoto.com
Sandoz has entered into a development and commercialisation agreement with pharmaceutical company Durect to develop the drug Posimir (Saber-bupivacaine).
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Sandoz, Durect, agreement, m&a, development, commercialisation, Posimir, pain relief
